Skip to content
10-Q

Quarterly Report

Gene Biotherapeutics, Inc.

0001493152-21-026416

← back to feed
Filed
Oct 27, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Oct 8, 2021 64.93M sh
Capex Q3 2020 · Sep 30, 2020 $3.43K
Operating Cash Flow Q3 2020 · Sep 30, 2020 −$795.14K
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$113.77K
Cash And Equivalents Q3 2020 · Sep 30, 2020 $781.57K
Cash And Equivalents Q3 2020 · Dec 31, 2019 $400
Stockholders Equity Q3 2020 · Sep 30, 2020 −$3.43M
Stockholders Equity Q3 2020 · Dec 31, 2019 −$4.29M
Current Liabilities Q3 2020 · Sep 30, 2020 $4.93M
Current Liabilities Q3 2020 · Dec 31, 2019 $4.76M
Total Liabilities Q3 2020 · Sep 30, 2020 $5.05M
Total Liabilities Q3 2020 · Dec 31, 2019 $4.89M
Current Assets Q3 2020 · Sep 30, 2020 $800.75K
Current Assets Q3 2020 · Dec 31, 2019 $32.8K
Total Assets Q3 2020 · Sep 30, 2020 $974.82K
Total Assets Q3 2020 · Dec 31, 2019 $35.44K
Sga Expense Q3 2020 · Sep 30, 2020 $322.58K
Sga Expense Q3 2020 · Sep 30, 2020 $622.4K
Sga Expense Q3 2020 · Sep 30, 2019 $114.05K
Sga Expense Q3 2020 · Sep 30, 2019 $474.12K
Rd Expense Q3 2020 · Sep 30, 2020 $66.12K
Rd Expense Q3 2020 · Sep 30, 2020 $161.84K
Rd Expense Q3 2020 · Sep 30, 2019 $61.44K
Rd Expense Q3 2020 · Sep 30, 2019 $185.18K
Net Income Q3 2020 · Sep 30, 2020 −$361.13K
Net Income Q3 2020 · Sep 30, 2020 −$75.11K
Net Income Q3 2020 · Sep 30, 2019 −$130.67K
Net Income Q3 2020 · Sep 30, 2019 −$583.41K
Operating Income Q3 2020 · Sep 30, 2020 −$388.7K
Operating Income Q3 2020 · Sep 30, 2020 −$184.24K
Operating Income Q3 2020 · Sep 30, 2019 −$175.49K
Operating Income Q3 2020 · Sep 30, 2019 −$659.3K